Nested case-control study of energy regulation candidate gene single nucleotide polymorphisms and breast cancer

Anticancer Research

Volumn 27, Issue 1 B, 2007, Pages 589-593

  Wang, Yiting ^a   Mc Cullough, Marjorie L ^a   Stevens, Victoria L ^a   Rodriguez, Carmen ^a   Jacobs, Eric J ^a   Teras, Lauren R ^a   Pavluck, Alexandre L ^a   Thun, Michael J ^a   Calle, Eugenia E ^a  

^a AMERICAN CANCER SOCIETY   (United States)

Author keywords

Insulin resistance; Postmenopausal breast cancer; Single nucleotide polymorphism

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC CORRELATION; GENETIC SCREENING; GENOTYPE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN RESISTANCE; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; RECEPTOR, INSULIN;

EID: 33847711073     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Loktionov A: Common gene polymorphisms and nutrition: emerging links with pathogenesis of multifactorial chronic diseases (review). J Nutr Biochem 14: 426-451, 2003.
2. Boyd DB: Insulin and cancer. Integr Cancer Ther 2: 315-329, 2003.
3. Kido Y, Nakae J and Accili D: Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 86: 972-979, 2001.
4. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE and Zeleniuch-Jacquotte A: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88: 828-832, 2000.
5. Lawlor DA, Smith GD and Ebrahim S: Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 15: 267-275, 2004.
6. Yang G, Lu G, Jin F, Dai Q, Best R, Shu XO, Chen JR, Pan XY, Shrubsole M and Zheng W: Population-based, case-control study of blood C-peptide level and breast cancer risk. Cancer Epidemiol Biomarkers Prev 10: 1207-1211, 2001.
7. Verheus M, Peelers PH, Rinaldi S, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Jeppesen M, Clavel-Chapelon F, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Arvaniti A, Psaltopoulou T, Trichopoulou A, Palli D, Tumino R, Panico S, Sacerdote C, Sieri S, van Gils CH, Bueno-de-Mesquita BH, Gonzalez CA, Ardanaz E, Larranaga N, Garcia CM, Navarro C, Quiros JR, Key T, Alien N, Bingham S, Khaw KT, Slimani N, Riboli E and Kaaks R: Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119: 659-667, 2006.
8. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M and Berrino F: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11: 1361-1368, 2002
9. Ho GY, Melman A, Liu SM, Li M, Yu H, Negassa A, Burk RD, Hsing AW, Ghavamian R and Chua SC Jr: Polymorphism of the insulin gene is associated with increased prostate cancer risk. Br J Cancer 88: 263-269, 2003.
10. Lucassen AM, Julier C, Beressi JP, Boitard C, Froguel P, Lathrop M and Bell JI: Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR. Nat Genet 4: 305-310, 1993.
11. Sanchez-Corona J, Flores-Martinez SE, Machorro-Lazo MV, Galaviz-Hernandez C, Moran-Moguel MC, Perea FJ, Mujica-Lopez KI, Vargas-Ancona L, Laviada-Molina HA, Fernandez V, Pardio J, Arroyo P, Barrera H and Hanson RL: Polymorphisms in candidate genes for type 2 diabetes mellitus in a Mexican population with metabolic syndrome findings. Diabetes Res Clin Pract 63: 47-55, 2004.
12. Li L, Cicek MS, Casey G and Witte JS: No association between genetic polymorphisms in insulin and insulin receptor substrate-1 and prostate cancer. Cancer Epidemiol Biomarkers Prev 14: 2462-2463, 2005.
13. Seino S, Seino M, Nishi S and Bell GI: Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 86: 114-118, 1989.
14. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M et al: Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756-761, 1985.
15. Siegel S, Futterweit W, Davies TF, Concepcion ES, Greenberg DA, Villanueva R and Tomer Y: A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril 78: 1240-1243, 2002.
16. Chen ZJ, Shi YH, Zhao YR, Li Y, Tang R, Zhao LX and Chang ZH: Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi 39: 582-585, 2004.
17. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y and Kinoshita Y: Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anti-Cane Agents 4: 465-477, 2004.
18. Rangwala SM and Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sei 25: 331-336, 2004.
19. Meirhaeghe A and Amouyel P: Impact of genetic variation of PPARgamma in humans. Mol Genet Metab 83: 93-102, 2004.
20. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
21. Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R and Nawata H: Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 271: 710-713, 2000.
22. Rubin GL, Zhao Y, Kalus AM and Simpson ER: Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res 60: 1604-1608, 2000.
23. Memisoglu A, Hankinson SE, Manson JE, Colditz GA and Hunter DJ: Lack of association of the codon 12 polymorphism of the peroxisome proliferator- activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 12: 597-603, 2002.
24. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W and Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20: 284-287, 1998.
25. Vogel U, Christensen J, Nexo BA, Wallin H, Friis S and Tjonneland A: Peroxisome profilerator-activated receptor {gamma}2 Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis, September 6, 2006 [Epub ahead of print].
26. Calle EE, Rodriguez C, Jacobs EJ, Almon ML, Chao A, McCullough ML, Feigelson HS and Thun MJ: The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer 94: 2490-2501, 2002.
27. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L and Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76-80, 2000.
28. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E and Kasuga M: The Pro12 → Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50: 891-894, 2001.